GlaxoSmithKline is set to launch its COPD triple therapy in the US - and must now show that it can maximise sales of the drug with blockbuster potential. Approved yesterday by the FDA, Trelegy ...

“This is the first long-term study to look at the possibilities of triple therapy as a preventative measure for COPD exacerbations. “COPD exacerbations lead to approximately 150,000 hospital ...

GlaxoSmithKline’s (GSK) triple therapy for chronic obstructive pulmonary disease (COPD) has been approved in Europe. The licence from the European Commission means Trelegy Ellipta is now ...

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on ...

With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

SAN DIEGO — Immunoglobulin G hypogammaglobulinemia was found in 44.7% of patients with acute exacerbations of COPD receiving triple therapy, according to a presentation here. This single-center ...

Conclusion: A 7-day rifabutin-based triple therapy associated to amoxicillin and omeprazole at standard dose was not found to be effective as a second-line rescue therapy. The problem with ...

Findings from the FABULAS study, published in The Lancet, describe initial results for Targeted Thermal Therapy (Triple T), which was tested in 28 patients with primary aldosteronism, whose ...